| Drug Name: | Citalopram (59729-33-8) |
|---|---|
| PubChem ID: | 2771 |
| SMILES: | CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F |
| InchiKey: | WSEQXVZVJXJVFP-UHFFFAOYSA-N |
| Therapeutic Category: | Antidepressive Agents, Central Nervous System Agents, Membrane Transport Modulators, Neurotransmitter Agents, Neurotransmitter Uptake Inhibitors, Psychotropic Drugs, Serotonin Agents, Serotonin Uptake Inhibitors |
| Molecular Weight (dalton) | : | 324.399 |
| LogP | : | 3.81298 |
| Ring Count | : | 2 |
| Hydrogen Bond Acceptor Count | : | 3 |
| Hydrogen Bond Donor Count | : | 0 |
| Total Polar Surface Area | : | 36.26 |
This panel provides information on interacting drugs and their ADRs along with references
| Interacting drug | Toxicity | Interaction Type | Mechanism | Reference |
|---|---|---|---|---|
| Linezolid (165800-03-3) | Agitation | Synergistic | Not fully understood | Serotonin syndrome and linezolid (Pubmed ID 15213578) |
| Linezolid (165800-03-3) | Confusion | Synergistic | Not fully understood | Serotonin syndrome and linezolid (Pubmed ID 15213578) |
| Linezolid (165800-03-3) | Dysarthria | Synergistic | Not fully understood | Serotonin syndrome and linezolid (Pubmed ID 15213578) |
| Linezolid (165800-03-3) | Hyperreflexia | Synergistic | Not fully understood | Serotonin syndrome and linezolid (Pubmed ID 15213578) |
| Linezolid (165800-03-3) | Restlessness | Synergistic | Not fully understood | Serotonin syndrome and linezolid (Pubmed ID 15213578) |
| Linezolid (165800-03-3) | Serotonin Syndrome | Synergistic | Not fully understood | Serotonin syndrome and linezolid (Pubmed ID 15213578) |
| Linezolid (165800-03-3) | Tremor | Synergistic | Not fully understood | Serotonin syndrome and linezolid (Pubmed ID 15213578) |
This panel provides drug-protein interaction and their ADRs along with references
| Toxicity | Interacting Protein | Mechanism | Reference |
|---|---|---|---|
| Toxicity And Inefficacy | CYP2D6 (P10635) | Toxicity in poor metabolisers@ inefficacy in ultrarapid metabolisers. [ ADR Type 3 ] | Drugs in special patient groups: clinical importance of genomics in drug effects In: Carruthers GS, Hoffmann BB,Melmon KL, Nierenberg DW |
This panel provides drug-food interactions and their ADRs along with references
| Food | Toxicity | Reference |
|---|
This panel provides information on metabolites and their ADRs along with references
| Metabolite | Toxicity | Place of Metabolism | Mechanism | Reference |
|---|
This panel provides information on drug category